Our Two Corporate Divisions
At Impax Laboratories our vision is to target key areas of growth that reflect both our internal strengths, and a strong market, treatment or product need. Our two divisions reflect this strategy.
Global Pharmaceuticals – Our Generics Division
In the generic pharmaceuticals market, we are primarily focusing our efforts on selected controlled-release generic versions of brand name pharmaceuticals. With a strong generic portfolio of products, and established distribution partners, we are focused on developing generic pharmaceuticals that present one or more competitive barriers to entry, such as difficulty sourcing raw materials, complex formulation or development characteristics, or special handling requirements.
Impax Pharmaceuticals – Our Brand Division
In the brand name pharmaceuticals market, we are developing products for the treatment of central nervous system, or CNS disorders. With a strong global need for the development of new treatments and new approaches, CNS disorders including Parkinson’s disease, multiple sclerosis, epilepsy, attention deficit disorder, migraines, depression, schizophrenia and Alzheimer's disease, make up the largest therapeutic category in the US (Wolters Kluwer Health data).